表紙
市場調查報告書

口腔乾燥症:開發中產品分析

Xerostomia - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 619903
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
口腔乾燥症:開發中產品分析 Xerostomia - Pipeline Review, H2 2019
出版日期: 2019年11月18日內容資訊: 英文 37 Pages
簡介

所謂口腔乾燥症,是由於唾液的分泌量減少造成口腔內部乾燥的疾病。主要的病因,是藥物治療和老齡化,癌症治療,傷害,脫水症狀,抽煙等。主要的症狀,有味覺功能失調和真菌感染疾病,口臭,舌頭潰瘍,會話障礙,唾液的粘著化等。主要的治療方法,包含刺激唾液分泌的藥物治療等。

本報告提供全球各國的口腔乾燥症的開發中產品的開發情形相關分析,開發中產品的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業的簡介,主要藥物概要,最新的產業趨勢 (臨床實驗調查中斷中/已中止的產品等) 等。

目錄

  • 簡介
    • 分析範圍
  • 口腔乾燥症概要
  • 口腔乾燥症:治療藥的開發
    • 開發平台概要
    • 各企業的開發平台趨勢
    • 企業開發中的產品
  • 口腔乾燥症:治療藥的評估
    • 各標的
    • 各作用機制
    • 各給藥途徑
    • 各分子類型
  • 口腔乾燥症:開發治療藥的企業
    • Acacia Pharma Ltd
    • Humanetics Corp
    • Icure Pharmaceutical Inc
    • Lamellar Biomedical Ltd
  • 口腔乾燥症:藥物的簡介
    • A-00X
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的進展
    • Bethanechol Chloride
    • BIO-300
    • 氧化鈰
    • CLX-156
    • 肺發炎、放射性皮膚炎、口腔乾燥症用醫藥品
    • ECF-843
    • LMS-611
    • 毛果芸香鹼
  • 肌肉萎縮症:暫停的計劃
  • 肌肉萎縮症:產品開發里程碑
    • 值得注意的最新趨勢、新聞稿(共4件)
  • 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11500IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Xerostomia - Pipeline Review, H2 2019, provides an overview of the Xerostomia (Mouth and Dental Disorders) pipeline landscape.

Xerostomia is defined as dry mouth resulting from reduced saliva flow. It is caused by medications, age, cancer treatment, injury, dehydration and chewing or smoking tobacco. Symptoms include dysgeusia, fungal infections, bad breath, tongue ulcers, problems speaking and sticky saliva. Treatment includes medications which stimulating saliva production.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Xerostomia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Xerostomia (Mouth and Dental Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Xerostomia (Mouth and Dental Disorders) pipeline guide also reviews of key players involved in therapeutic development for Xerostomia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 3, 1 and 1 respectively.

Xerostomia (Mouth and Dental Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Xerostomia (Mouth and Dental Disorders).
  • The pipeline guide reviews pipeline therapeutics for Xerostomia (Mouth and Dental Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Xerostomia (Mouth and Dental Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Xerostomia (Mouth and Dental Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Xerostomia (Mouth and Dental Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Xerostomia (Mouth and Dental Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Xerostomia (Mouth and Dental Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Xerostomia - Overview
  • Xerostomia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Xerostomia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Xerostomia - Companies Involved in Therapeutics Development
    • BioCurity Pharmaceuticals Inc
    • Capricor Therapeutics Inc
    • Humanetics Corp
    • Icure Pharmaceutical Inc
    • Lubris Biopharma
    • MeiraGTx Holdings Plc
    • MyX Therapeutics Inc
  • Xerostomia - Drug Profiles
    • A-00X - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAP-2003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cerium oxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Xerostomia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Enteritis, Proctitis, Pulmonary Inflammation, Radiodermatitis, and Xerostomia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • genistein - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBS-020 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pilocarpine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Xerostomia - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Xerostomia, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Xerostomia - Pipeline by BioCurity Pharmaceuticals Inc, H2 2019
  • Xerostomia - Pipeline by Capricor Therapeutics Inc, H2 2019
  • Xerostomia - Pipeline by Humanetics Corp, H2 2019
  • Xerostomia - Pipeline by Icure Pharmaceutical Inc, H2 2019
  • Xerostomia - Pipeline by Lubris Biopharma, H2 2019
  • Xerostomia - Pipeline by MeiraGTx Holdings Plc, H2 2019
  • Xerostomia - Pipeline by MyX Therapeutics Inc, H2 2019
  • Xerostomia - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Xerostomia, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top